---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-090056"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2026-08-04T11:08:37+00:00"
generated_at: "2026-08-04T11:10:11.656837+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TELA Bio CEO Antony Koblish departs; Heather Getz appointed CEO and director

## Summary
- Antony Koblish ceased as CEO and resigned from board on Aug 3, 2026; no disagreement with company.
- Heather Getz appointed CEO and Class II director effective Aug 3, 2026; 25+ years healthcare experience.
- Employment agreement: $650k base salary, 100% target bonus, severance, and initial equity grants.
- Initial equity grants: 1,365,000 standard options, 1,005,000 premium-priced options, 500,000 RSUs.
- Potential top-up grants if equity financings within 18 months; total could reach 5% of outstanding shares.

## SEC filing metadata
- accession: 0001104659-26-090056
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2026-08-04T11:08:37+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465926090056/0001104659-26-090056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465926090056/tm2622121d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-090056
- JSON: https://secwatch.observer/filing/0001104659-26-090056.json
- Plain text: https://secwatch.observer/filing/0001104659-26-090056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.